Winton Group’s Nuvation Bio NUVB Stock Holding History

Winton Group’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-30,350	Closed	-$88.6K	–	731
2024 Q2	$88.6K	Buy	+30,350	New	+$92.6K	0.01%	550

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Winton Group's NUVB Position: Q3 2024 in Review

Winton Group sold out of Nuvation Bio (NUVB) in Q3 2024, closing a stake of 30,350 shares — an estimated $88.6K sold.

Winton Group first reported a position in NUVB in Q2 2024 and held it in 1 quarter. The position peaked at $88.6K in Q2 2024. 154 funds tracked by Wall St. Rank hold NUVB as of Q3 2024.

Winton Group reported no remaining Nuvation Bio position as of Q3 2024 after selling out during the quarter.
Winton Group sold 30,350 Nuvation Bio shares in Q3 2024, an estimated $88.6K.
Winton Group first reported a position in Nuvation Bio in Q2 2024 and held it in 1 quarter.
Winton Group's Nuvation Bio position peaked at $88.6K in Q2 2024.
154 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2024.

Based on Winton Group's 13F filing for Q3 2024, filed 12 Nov 2024.